35 Gatehouse Drive
19 articles with Skyhawk Therapeutics
Skyhawk Therapeutics Expands Leadership Team with Chief Medical Officer and Head of Chemistry, and adds to its Scientific Advisory Board
Joseph Duffy PhD brings 20+ years of small molecule discovery chemistry and operations to his role as SVP Chemistry of Skyhawk Therapeutics, Elliot Ehrich MD brings 20+ years of clinical development for novel pharmaceuticals to his role as Chief Medical Officer of Skyhawk Therapeutics, and Rob Hershberg MD-PhD with 25+ years of biotech and pharma experience has jo
Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing.
The two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.
Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer at Skyhawk Therapeutics
Dr. Terrance Connolly brings over 20 years of biotech operations and business development experience to his role as Chief Operating Officer Skyhawk Therapeutics . WALTHAM, Mass. , Feb. 24, 2020 /PRNewswire/ -- Skyhawk Therapeutics, Inc. ("Skyhawk" or the "Company") today announced Dr. Terrance ("Terry") Connolly will become its Chief Operating Officer. Dr. Connolly w
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (NASDAQ: CELG).
The company expands its Scientific Advisory Board with four additional RNA splicing, genetics, and disease experts, who join SAB Chair Professor Tyler Jacks & special advisor Professor Phil Sharp as well as several other internationally-recognized SAB members.
Skyhawk Therapeutics, Inc. ("Skyhawk"), today announced Dr. Phillip Sharp has joined as special advisor to its Scientific Advisory Board.
Skyhawk Therapeutics Announces Agreement with Genentech to Discover and Develop Small Molecule RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases
Skyhawk will use its SkySTARTM platform to develop drug candidates directed to multiple targets for oncology and neurodegenerative diseases.
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
7/12/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
Skyhawk to expand its collaboration with Biogen to develop novel small molecule RNA splicing modifiers for disease targets
Skyhawk Therapeutics Announces Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk will deploy its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases and cancer
Tyler Jacks, Ph.D., head of the Koch Institute for Integrative Cancer Research at MIT, joins as Chair of Skyhawk's Scientific Advisory Board
Skyhawk and Merck will partner to discover and develop innovative RNA-binding small molecules that can form treatments for neurological diseases and cancer.
Skyhawk Therapeutics Announces Agreement with Takeda to Develop Novel Small Molecule RNA Splicing Modifiers for Neurodegenerative Diseases
Skyhawk will use its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases. In exchange Takeda will pay Skyhawk an upfront payment, future milestone payments and royalties.
2/15/2019Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs successfully to patients.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's SkySTAR™ platform